BR9709942A - Uso de um composto composição farmacêutica embalagem e processo de tratamento de organismo de animal humano ou não humano para combater ou prevenircondições associadas com a presença de radicais livres no organismo - Google Patents

Uso de um composto composição farmacêutica embalagem e processo de tratamento de organismo de animal humano ou não humano para combater ou prevenircondições associadas com a presença de radicais livres no organismo

Info

Publication number
BR9709942A
BR9709942A BR9709942A BR9709942A BR9709942A BR 9709942 A BR9709942 A BR 9709942A BR 9709942 A BR9709942 A BR 9709942A BR 9709942 A BR9709942 A BR 9709942A BR 9709942 A BR9709942 A BR 9709942A
Authority
BR
Brazil
Prior art keywords
human
combat
pharmaceutical composition
treatment process
free radicals
Prior art date
Application number
BR9709942A
Other languages
English (en)
Portuguese (pt)
Inventor
Jan Olof Gustav Karlsson
Per Jynge
Robertson Towart
Original Assignee
Nycomed Imaging As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed Imaging As filed Critical Nycomed Imaging As
Publication of BR9709942A publication Critical patent/BR9709942A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/32—Manganese; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preventing Corrosion Or Incrustation Of Metals (AREA)
  • Semiconductor Lasers (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Manufacture And Refinement Of Metals (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
BR9709942A 1996-06-24 1997-06-24 Uso de um composto composição farmacêutica embalagem e processo de tratamento de organismo de animal humano ou não humano para combater ou prevenircondições associadas com a presença de radicais livres no organismo BR9709942A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9613182.6A GB9613182D0 (en) 1996-06-24 1996-06-24 Method
PCT/GB1997/001722 WO1997049409A1 (en) 1996-06-24 1997-06-24 Chelating agents and their metal chelates for treating free radicals induced conditions

Publications (1)

Publication Number Publication Date
BR9709942A true BR9709942A (pt) 1999-08-10

Family

ID=10795775

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9709942A BR9709942A (pt) 1996-06-24 1997-06-24 Uso de um composto composição farmacêutica embalagem e processo de tratamento de organismo de animal humano ou não humano para combater ou prevenircondições associadas com a presença de radicais livres no organismo

Country Status (14)

Country Link
US (2) US6147094A (enExample)
EP (2) EP0936915B1 (enExample)
JP (2) JP4162263B2 (enExample)
CN (2) CN1228703A (enExample)
AT (2) ATE225178T1 (enExample)
AU (2) AU720621B2 (enExample)
BR (1) BR9709942A (enExample)
CA (2) CA2258299A1 (enExample)
DE (2) DE69716104T2 (enExample)
GB (1) GB9613182D0 (enExample)
IL (1) IL127733A0 (enExample)
NO (2) NO985917L (enExample)
NZ (2) NZ333357A (enExample)
WO (2) WO1997049409A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9727224D0 (en) * 1997-12-23 1998-02-25 Nycomed Imaging As Method
JP2001527072A (ja) * 1997-12-23 2001-12-25 ニユコメド・イメージング・アクシエセルカペト 一酸化窒素を放出するキレート化剤およびその治療上の使用
US7592304B2 (en) 1999-10-01 2009-09-22 Dmi Life Sciences, Inc. Metal-binding compounds and uses therefor
US7632803B2 (en) 1999-10-01 2009-12-15 Dmi Life Sciences, Inc. Metal-binding compounds and uses therefor
JP5349722B2 (ja) 1999-10-01 2013-11-20 ディーエムアイ バイオサイエンシズ インコーポレイテッド 金属結合化合物およびその使用方法
FR2823977B1 (fr) * 2001-04-26 2006-12-01 Univ Rene Descartes Utilisation du mangafodipir dans le traitement des effets d'un stress oxydatif
GB0117645D0 (en) 2001-07-19 2001-09-12 Isis Innovation Therapeutic stratergies for prevention and treatment of alzheimers disease
US20040038904A1 (en) * 2002-05-21 2004-02-26 Angela Ogden Method of treating multiple sclerosis
FR2863892B1 (fr) * 2003-12-18 2007-05-11 Univ Paris Descartes Utilisation de mimetiques de la superoxyde dismutase et de la glutathion reductase comme anti-cancereux
JP4972545B2 (ja) 2004-04-22 2012-07-11 セレーター ファーマスーティカルズ、インク. アントラサイクリン系薬剤及びシチジンアナログのリポソーム製剤
US7771751B2 (en) 2005-08-31 2010-08-10 Abraxis Bioscience, Llc Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents
EP2224925B1 (en) 2007-12-14 2015-09-09 Pledpharma AB Compounds for use in the treatment of cancer
KR101939207B1 (ko) * 2009-07-06 2019-01-16 플레드파르마 에이비 망간 착물 화합물 및 비 망간 착물 형태의 화합물의 조합을 사용하는 약학적 조성물 및 치료 방법
HUE048876T2 (hu) 2011-05-09 2020-08-28 Mayo Found Medical Education & Res Rákos megbetegedések kezelése
BR112014016497B1 (pt) 2012-01-05 2021-02-23 Pledpharma Ab complexos de metal misturados, composição farmacêutica compreendendo os mesmos, métodos de produção e uso
US10413606B2 (en) 2012-10-01 2019-09-17 Mayo Foundation For Medical Education And Research Methods for treating cancer with nanoparticle complexes of albumin-bound paclitaxel and anti-VEGF antibodies
US20150313921A1 (en) 2012-11-02 2015-11-05 Pledpharma Ab Cancer Treatment Methods
EP3154586B1 (en) 2014-06-13 2020-05-27 Mayo Foundation for Medical Education and Research Treating lymphomas
US10213513B2 (en) 2014-06-16 2019-02-26 Mayo Foundation For Medical Education And Research Treating myelomas
CN107073132B (zh) 2014-10-06 2021-08-27 梅约医学教育与研究基金会 载体-抗体组合物及其制备和使用方法
TW201707725A (zh) 2015-08-18 2017-03-01 美國馬友醫藥教育研究基金會 載體-抗體組合物及其製造及使用方法
TW201713360A (en) 2015-10-06 2017-04-16 Mayo Foundation Methods of treating cancer using compositions of antibodies and carrier proteins
WO2017120501A1 (en) 2016-01-07 2017-07-13 Mayo Foundation For Medical Education And Research Methods of treating cancer with interferon
US11351254B2 (en) 2016-02-12 2022-06-07 Mayo Foundation For Medical Education And Research Hematologic cancer treatments
EP3432928A4 (en) 2016-03-21 2019-11-20 Mayo Foundation for Medical Education and Research PROCESS FOR IMPROVING THE THERAPEUTIC INDEX FOR CHEMOTHERAPEUTIC
WO2017165440A1 (en) * 2016-03-21 2017-09-28 Mayo Foundation For Medical Education And Research Methods for reducing toxicity of a chemotherapeutic drug
US10618969B2 (en) 2016-04-06 2020-04-14 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
CN109890419A (zh) 2016-09-01 2019-06-14 梅约医学教育与研究基金会 用于治疗癌症的载体-pd-l1结合剂组合物
CN109843336A (zh) 2016-09-01 2019-06-04 梅约医学教育与研究基金会 用于靶向t细胞癌症的方法和组合物
AU2017324947A1 (en) 2016-09-06 2019-03-28 Mayo Foundation For Medical Education And Research Paclitaxel-albumin-binding agent compositions and methods for using and making the same
CN109843924A (zh) 2016-09-06 2019-06-04 梅约医学教育与研究基金会 治疗表达pd-l1的癌症的方法
US11590098B2 (en) 2016-09-06 2023-02-28 Mayo Foundation For Medical Education And Research Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES444380A1 (es) * 1976-01-16 1977-06-16 Gosalvez Mario Un procedimiento para preparar derivados metalicos antraci- clinicos.
US4842845A (en) * 1987-05-08 1989-06-27 Salutar, Inc. Radioactive metal chelates for dipyridoxyl phosphate
US5223243A (en) * 1987-05-08 1993-06-29 Salutar, Inc. Dipyridoxyl phosphate chelating compound intermediates useful as NMRI contrast agents
US4935518A (en) * 1987-05-08 1990-06-19 Salutar, Inc. Manganese(II), chelate contrast agents derived from N,N'-bis-(pyridoxal ethylene diamine-N,N')-diacetic acid and derivatives thereof
US6204259B1 (en) * 1993-01-14 2001-03-20 Monsanto Company Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide

Also Published As

Publication number Publication date
DE69716104T2 (de) 2003-05-28
NZ333315A (en) 2000-07-28
EP0910360A1 (en) 1999-04-28
NO985917L (no) 1999-01-25
IL127733A0 (en) 1999-10-28
CA2258299A1 (en) 1997-12-31
ATE228361T1 (de) 2002-12-15
CA2259150A1 (en) 1997-12-31
ATE225178T1 (de) 2002-10-15
DE69717447T2 (de) 2003-09-11
NZ333357A (en) 2000-08-25
US6258828B1 (en) 2001-07-10
NO985917D0 (no) 1998-12-17
AU720570B2 (en) 2000-06-08
JP2000514044A (ja) 2000-10-24
JP4162263B2 (ja) 2008-10-08
NO985916L (no) 1999-01-25
CN1228694A (zh) 1999-09-15
NO985916D0 (no) 1998-12-17
JP2000513351A (ja) 2000-10-10
US6147094A (en) 2000-11-14
AU3268897A (en) 1998-01-14
AU720621B2 (en) 2000-06-08
DE69716104D1 (de) 2002-11-07
EP0936915A1 (en) 1999-08-25
EP0910360B1 (en) 2002-11-27
WO1997049390A1 (en) 1997-12-31
JP4359651B2 (ja) 2009-11-04
AU3268997A (en) 1998-01-14
CN1228703A (zh) 1999-09-15
WO1997049409A1 (en) 1997-12-31
DE69717447D1 (de) 2003-01-09
GB9613182D0 (en) 1996-08-28
EP0936915B1 (en) 2002-10-02

Similar Documents

Publication Publication Date Title
AU3268997A (en) Chelating agents and their metal chelates for treating free radicals induced conditions
TR200201067T2 (tr) Bir tramadol maddesi ve bir antikonvülsan ilaç içeren bileşimler
TW200518752A (en) Combinations of drugs for the treatment of neoplasms
AU1770299A (en) Nitric oxide releasing chelating agents and their therapeutic use
PT101289A (pt) Utilizacao de taxol para a preparacao de composicoes farmaceuticas de eficacia melhorada
TR200002243T2 (tr) Arsenik trioksitin hazırlanması için işlem ve bunların kanser tedavisi için kullanımı.
PT1039887E (pt) Metodos para o tratamento de neuro e nefro disturbios e de toxicidades terapeuticas usando compostos de aminotiol
PT1129093E (pt) Derivados de pirazpolopirimidinona para o tratamento da impotencia
BR0109517A (pt) métodos e composições sinérgicas para tratar o cáncer
BR0009647A (pt) Docetaxel em combinação com rhumab her2 para o tratamento de cânceres
WO2004006842A3 (en) Combinations of drugs for the treatment of neoplasms
BR9811946A (pt) Método para prevenção ou tratamento de distúrbios e doenças dependentes de estrogênio
BR0207487A (pt) Método de tratamento de tumores em mamìferos e uso de compostos de epotilona
EP1140198A4 (en) COMPOSITION FOR INCREASING THE EFFECTIVENESS OF MEDICINES AND RELATED METHODS
EP0934065A4 (en) PHARMACEUTICAL COMPOSITION
WO2005011572A3 (en) Combination of drugs for the treatment of neoplasms
DE69835824D1 (de) Antitumorkombination aus 3-amino-1,2,4-benzotriazine 1,4-dioxid/paclitaxel/platin
GB2368525A (en) Hyaluronan as a cytotoxic agent, drug pre-sensitizer and chemo-sensitizer in the treatment of disease
BR9712141A (pt) Aplicação de 1-hifróxi-2-piridonas para tratamento de infecções cutâneas.
ZA963784B (en) Terpenoidic derivatives useful as antitumor agents.
DE69626544D1 (de) Arzneistoffe
MX9800697A (es) Uso de glicosidos de calendula para el tratamiento de psoriasis.

Legal Events

Date Code Title Description
FB36 Technical and formal requirements: requirement - article 36 of industrial property law
FA8 Dismissal: dismissal - article 36, par. 1 of industrial property law